- Partner Sanofi advances SAR’514 / IPH6401, a trifunctional
anti-BCMA NKp46xCD16 NK cell engager from a joint research
collaboration between Innate Pharma and Sanofi, to first-in-human
clinical trial in relapsed/refractory Multiple Myeloma (RRMM) and
Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
- Second molecule from Innate’s multi-specific NK cell engager
platform ANKET® to progress to the clinic
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that the
first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical
trial (NCT05839626), evaluating SAR’514 / IPH6401 in
relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory
Light-chain Amyloidosis (RRLCA)1.
SAR’514 is a trifunctional anti-BCMA NKp46xCD16 NK cell engager,
using Sanofi’s proprietary CROSSODILE® multi-functional platform,
which comprises the Cross-Over-Dual-Variable-Domain (CODV) format.
It induces a dual targeting of the NK activating receptors, NKp46
and CD16, for an optimized NK cell activation, based on Innate’s
ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary
platform.
The purpose of the dose escalation and dose expansion study is
to evaluate the safety, pharmacokinetics and preliminary efficacy
of SAR’514 in monotherapy in patients with RRMM and RRLCA.
Joyson Karakunnel, MD, MSc, FACP, Chief Medical Officer at
Innate Pharma “We are pleased to see a second molecule from our
ANKET® platform reaching the clinic. In addition to the targeting
of the tumor antigen BCMA, SAR’514 / IPH6401 co-engages the two
activating receptors NKp46 and CD16 to leverage the advantages of
harnessing NK cell effector functions against cancer cells and thus
has the potential to be a new innovative option for patients living
with Relapsed/Refractory Multiple Myeloma or Light-chain
Amyloidosis.”
Peter Adamson, MD, Global Development Head, Oncology,
Sanofi “We are excited to see our collaboration with Innate
Pharma continue to move forward, leveraging scientific advances in
our understanding of the potential of NK cells to impact cancer.
Our first patient dosed with SAR’514 / IPH6401 is indeed welcome
news. We look forward to data as it emerges, with the goal of
improving the outcome for patients with relapsed/refractory
multiple myeloma (RRMM) or relapsed/refractory light-chain
amyloidosis (RRLCA).”
The start of the trial has triggered a milestone payment from
Sanofi to Innate, which is part of a previously announced research
collaboration with Sanofi.
More information about the Phase 1/2 trial can be found on
clinicaltrials.gov.
About ANKET®
ANKET® (Antibody-based NK cell Engager
Therapeutics) is Innate's proprietary platform for
developing next-generation, multi-specific natural killer (NK) cell
engagers to treat certain types of cancer.
This versatile, fit-for-purpose technology is creating an
entirely new class of molecules to induce synthetic immunity
against cancer.
About the Innate-Sanofi agreements:
The Company has a research collaboration and license agreement
with Sanofi to apply Innate’s proprietary technology to the
development of innovative multi-specific antibody formats engaging
NK cells through the activating receptors NKp46 and CD16 to kill
tumor cells.
Under the terms of the 2016 research collaboration and license
agreement, Sanofi is responsible for the development, manufacturing
and commercialization of products resulting from the research
collaboration, which includes IPH6101/SAR’579 (Trifunctional
anti-CD123 NKp46xCD16 NK cell engager) and IPH6401/SAR’514
(Trifunctional anti-BCMA NKp46xCD16 NK cell engager). As part of
the 2016 agreement, Innate Pharma will be eligible to up to €400m
in development and commercial milestone payments as well as
royalties on net sales.
Another license agreement was entered in December 2022, which
includes IPH62 and 2 options.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code Ticker
code LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
1 Amyloidosis is a disease linked to the accumulation in various
organs and tissues of deposits of amyloid substance made up of
monoclonal light chains forming insoluble fibrils. These deposits
progressively impair the functioning of the affected organs and
tissues. Up to 30% of patients with multiple myeloma have
coexisting subclinical primary amyloidosis (Rajkumar SV, Gertz MA,
Kyle RA. Primary systemic amyloidosis with delayed progression to
multiple myeloma. Cancer. 1998;82:1501–5).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230710936341/en/
Investors Innate
Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (NASDAQ:IPHA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Innate Pharma (NASDAQ:IPHA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024